Developing New Immunotherapies to Advance the Cancer Treatment Paradigm
VentiRx is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases. VentiRx has a broad clinical pipeline. The lead clinical oncology asset, motolimod, is a small molecule TLR8 agonist, currently in multiple clinical trials in combination with chemotherapies and monoclonal antibodies. The company has entered into a worldwide strategic collaboration with Celgene Corporation for this program.
TLR8 Product Pipeline
Based in Seattle, Washington, VentiRx is a private company founded in 2006 with $53.9M in venture financing from Arch Venture Partners, Domain Associates, Frazier Healthcare Ventures and Medimmune Ventures.